ISRG

$477.97-1.96 (-0.41%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Intuitive Surgical, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$477.97
Potential Downside
65.5%
Whystock Fair Value$165.11
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$169.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
60.58
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
14.63%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.96

Recent News

Insider Monkey
Mar 21, 2026

Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?

Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on MTC’s Substack. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $483.46 as of March 16th. ISRG’s trailing and forward P/E were 59.99 and 47.39 respectively according to Yahoo Finance. Intuitive […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 21, 2026

Jim Cramer on Intuitive Surgical: “It’s Just Gotten Too Expensive Per Share”

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. A caller asked which of the three metrics is most important for the company: procedure growth, system placements, or hospital utilization. Cramer replied: It’s hospital utilization, and what gets me down […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 20, 2026

Should You Continue to Hold Insulet Stock in Your Portfolio?

PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could challenge its near-term performance.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 20, 2026

Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio

AMN rides MSP momentum, AI investments and surging labor disruption demand, but pricing pressure and volatile healthcare trends cloud its near-term outlook.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 20, 2026

GEHC Acquires Intelerad to Boost Cloud-First, AI Imaging Capabilities

GE HealthCare completes the $2.3B Intelerad deal to expand AI-driven imaging, boost recurring revenues and strengthen its cloud-first healthcare platform.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.